MCID: DBT005
MIFTS: 53

Diabetes Insipidus malady

Categories: Endocrine diseases, Nephrological diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Diabetes Insipidus

Aliases & Descriptions for Diabetes Insipidus:

Name: Diabetes Insipidus 12 29 41 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9409
ICD10 33 E23.2
ICD9CM 35 253.5
MeSH 42 D003919
NCIt 47 C43263
SNOMED-CT 64 15771004 190484000
UMLS 69 C0011848

Summaries for Diabetes Insipidus

MedlinePlus : 41 diabetes insipidus (di) causes frequent urination. you become extremely thirsty, so you drink. then you urinate. this cycle can keep you from sleeping or even make you wet the bed. your body produces lots of urine that is almost all water. di is different from diabetes mellitus (dm), which involves insulin problems and high blood sugar. the symptoms can be similar. however, di is related to how your kidneys handle fluids. it's much less common than dm. urine and blood tests can show which one you have. usually, di is caused by a problem with your pituitary gland or your kidneys. treatment depends on the cause of the problem. medicines can often help. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Diabetes Insipidus is related to bipolar disorder and diabetes insipidus, nephrogenic. An important gene associated with Diabetes Insipidus is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Neuroscience. The drugs Norepinephrine and Zinc have been mentioned in the context of this disorder. Affiliated tissues include pituitary, kidney and testes, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 71 Diabetes insipidus (DI) is a condition characterized by excessive thirst and excretion of large amounts... more...

Related Diseases for Diabetes Insipidus

Diseases in the Diabetes Insipidus family:

Hereditary Central Diabetes Insipidus Acquired Central Diabetes Insipidus

Diseases related to Diabetes Insipidus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 311)
id Related Disease Score Top Affiliating Genes
1 bipolar disorder 29.4 CLCNKA REN SLC12A1
2 diabetes insipidus, nephrogenic 12.8
3 diabetes insipidus, neurohypophyseal 12.8
4 hereditary central diabetes insipidus 12.2
5 acquired central diabetes insipidus 12.2
6 gestational diabetes insipidus 12.1
7 dipsogenic diabetes insipidus 12.1
8 wolfram syndrome 12.1
9 diabetes insipidus, nephrogenic, with mental retardation and intracerebral calcification 12.0
10 x-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome 11.9
11 wolfram syndrome 2 11.1
12 wolfram-like syndrome, autosomal dominant 10.9
13 polyhydramnios, megalencephaly, and symptomatic epilepsy 10.9
14 morgagni-stewart-morel syndrome 10.9
15 chromosome xq28 duplication syndrome 10.3 AVP AVPR2
16 diverticulitis of colon 10.3 AVP AVPR2
17 histiocytosis 10.3
18 hypopituitarism 10.2
19 macular retinal edema 10.2 AVP POMC
20 bagassosis 10.2 AVP POMC
21 childhood kidney cell carcinoma 10.2 AVP POMC
22 leukemia 10.2
23 transsexualism 10.2 AVP REN
24 generalized anxiety disorder 10.2 AVPR2 POMC
25 african histoplasmosis 10.2 POMC PRL
26 lymphocytic hypophysitis 10.2
27 congenital tricuspid stenosis 10.1 POMC PRL
28 distal monosomy 14q 10.1 POMC REN
29 hypogonadism mitral valve prolapse mental retardation 10.1 POMC REN
30 extragonadal nonseminomatous germ cell tumor 10.1 POMC PRL
31 wheat allergy 10.1 POMC PRL
32 cerebritis 10.1
33 pancreatic colloid cystadenoma 10.1 POMC PRL
34 endometrial mixed adenocarcinoma 10.1 POMC REN
35 gonococcal seminal vesiculitis 10.1 AVP POMC
36 bone benign neoplasm 10.1 AVP POMC PRL
37 hyperaldosteronism, familial, type iii 10.1 REN SLC12A1
38 gestational diabetes 10.1
39 mucopolysaccharidosis type vi 10.1 AVP POMC PRL
40 seow najjar syndrome 10.1 AVP INS
41 syringomelia hyperkeratosis 10.1 AQP2 AVP AVPR2 POMC
42 brain injury 10.1
43 renal tubular acidosis 10.1
44 traumatic brain injury 10.1
45 hydronephrosis 10.0
46 myeloid leukemia 10.0
47 breast secretory carcinoma 10.0 CRH POMC
48 early-onset parkinson disease 10.0 AVPR2 CRH POMC
49 lymphoma 10.0
50 fanconi syndrome 10.0

Comorbidity relations with Diabetes Insipidus via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetes Insipidus, Nephrogenic
Hypothyroidism Pituitary Hormone Deficiency, Combined, 2

Graphical network of the top 20 diseases related to Diabetes Insipidus:



Diseases related to Diabetes Insipidus

Symptoms & Phenotypes for Diabetes Insipidus

MGI Mouse Phenotypes related to Diabetes Insipidus:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.06 INS POMC PRL REN SLC12A1 WFS1
2 growth/size/body region MP:0005378 9.91 INS POMC REN SLC12A1 WFS1 AQP2
3 homeostasis/metabolism MP:0005376 9.9 AQP2 AQP3 AVP AVPR2 CRH INS
4 integument MP:0010771 9.56 AQP2 AVPR2 CRH INS POMC PRL
5 renal/urinary system MP:0005367 9.28 AQP2 AQP3 AVP AVPR2 CRH INS

Drugs & Therapeutics for Diabetes Insipidus

Drugs for Diabetes Insipidus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 313)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
2
Zinc Approved Phase 4 7440-66-6 32051 23994
3
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 51-43-4 5816
4
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54-31-9 3440
5
Conivaptan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 210101-16-9 151171
6
Tolvaptan Approved Phase 4,Phase 2,Phase 3,Phase 1 150683-30-0 216237
7
Benzocaine Approved Phase 4,Phase 2 1994-09-7, 94-09-7 2337
8
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 5754 657311
9
Misoprostol Approved Phase 4 59122-46-2 5282381
10
Phenylephrine Approved Phase 4,Phase 2 59-42-7 6041
11
Oxymetazoline Approved Phase 4,Phase 2 1491-59-4 4636
12
Ephedrine Approved Phase 4,Phase 2 299-42-3 9294
13
Pseudoephedrine Approved Phase 4,Phase 2 90-82-4 7028
14
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
15
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
16
Metolazone Approved Phase 4,Phase 1 17560-51-9 4170
17 tannic acid Approved, Nutraceutical Phase 4,Phase 2
18
Butyric Acid Experimental Phase 4,Phase 3 107-92-6 264
19
Synephrine Experimental Phase 4 1994-07-5, 94-07-5 7172
20 insulin Phase 4
21 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
22 diuretics Phase 4,Phase 3,Phase 2,Phase 1
23 Mydriatics Phase 4,Phase 3,Phase 2,Phase 1
24 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Natriuretic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1
27 Coagulants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1
29 Sodium Potassium Chloride Symporter Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
30 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2,Phase 1
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Hemostatics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Deamino Arginine Vasopressin Phase 4,Phase 3,Phase 2,Phase 1
34 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
35 Oxytocics Phase 4,Phase 2,Phase 1,Early Phase 1
36 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Vasopressins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Epinephryl borate Phase 4,Phase 3,Phase 2,Phase 1
41 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1
42 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Insulin, Globin Zinc Phase 4
44 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Racepinephrine Phase 4,Phase 3,Phase 2,Phase 1
46 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
47 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Arginine Vasopressin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 314)
id Name Status NCT ID Phase
1 Normoglycemia and Neurological Outcome Unknown status NCT01137773 Phase 4
2 Desmopressin for Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Bladder Reconstruction Unknown status NCT01582542 Phase 4
3 Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study Unknown status NCT01439997 Phase 4
4 Desmopressin for Bleeding Related to Low Body Temperature Unknown status NCT00902057 Phase 4
5 Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Unknown status NCT01716611 Phase 4
6 Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites Unknown status NCT01552590 Phase 4
7 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy Completed NCT00748072 Phase 4
8 Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest Completed NCT00127907 Phase 4
9 Desmopressin in Cardiac Surgery Completed NCT00337766 Phase 4
10 Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity Completed NCT00902655 Phase 4
11 Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy Completed NCT01700478 Phase 4
12 Desmopressin Melt: Impact on Sleep and Daytime Functioning Completed NCT01645475 Phase 4
13 Effects of Tolvaptan in Healthy Adults Completed NCT01973140 Phase 4
14 Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery Completed NCT02125188 Phase 4
15 Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery Completed NCT01994330 Phase 4
16 Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study Completed NCT01435083 Phase 4
17 Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation Completed NCT01036841 Phase 4
18 A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis Completed NCT00245479 Phase 4
19 A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE) Completed NCT00209261 Phase 4
20 Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial Completed NCT01393704 Phase 4
21 Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial Completed NCT00799292 Phase 4
22 Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients Completed NCT01752543 Phase 4
23 Effects of Vasopressors on Immune Response Completed NCT02675868 Phase 4
24 Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients Completed NCT01439009 Phase 4
25 Pilot Study of Using Copeptin to Predict Response to Tolvaptan Completed NCT01346072 Phase 4
26 Tolvaptan for Ascites in Cirrhotic Patients Completed NCT01292304 Phase 4
27 Tolvaptan in Hyponatremic Cancer Patients Completed NCT01199198 Phase 4
28 A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia Completed NCT00435591 Phase 4
29 Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure Completed NCT01863511 Phase 4
30 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4
31 Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population Recruiting NCT02584231 Phase 4
32 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4
33 Regional Tolvaptan Registry Recruiting NCT02666651 Phase 4
34 Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure Recruiting NCT02352285 Phase 4
35 Tolvaptan for Advanced or Refractory Heart Failure Recruiting NCT02959411 Phase 4
36 Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders Recruiting NCT02476409 Phase 4
37 Vasoactive Drugs in Intensive Care Unit Recruiting NCT02118467 Phase 4
38 Aquaresis Utility for Hyponatremic Acute Heart Failure Study Recruiting NCT02183792 Phase 4
39 NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock Active, not recruiting NCT02454348 Phase 4
40 Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure Enrolling by invitation NCT02606253 Phase 4
41 DDAVP vs. Exercise Not yet recruiting NCT03136003 Phase 4
42 Vasoactive Hormones and Oxygen Saturation During Apneic Events in Patients With Obstructive Sleep Apnea Suspended NCT00438412 Phase 4
43 Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery Terminated NCT00885924 Phase 4
44 Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease Terminated NCT00806468 Phase 4
45 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4
46 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4
47 Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine Withdrawn NCT00298753 Phase 4
48 Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion Withdrawn NCT00806910 Phase 4
49 The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study Withdrawn NCT01663662 Phase 4
50 Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients Unknown status NCT01718613 Phase 3

Search NIH Clinical Center for Diabetes Insipidus

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: diabetes insipidus

Genetic Tests for Diabetes Insipidus

Genetic tests related to Diabetes Insipidus:

id Genetic test Affiliating Genes
1 Diabetes Insipidus 29

Anatomical Context for Diabetes Insipidus

MalaCards organs/tissues related to Diabetes Insipidus:

39
Pituitary, Kidney, Testes, Brain, Myeloid, Thyroid, Liver

Publications for Diabetes Insipidus

Articles related to Diabetes Insipidus:

(show top 50) (show all 1243)
id Title Authors Year
1
Value of Renal Biopsy in Diagnosing Infantile Nephropathic Cystinosis Associated With Secondary Nephrogenic Diabetes Insipidus. ( 28276300 )
2017
2
Transient Diabetes Insipidus After Discontinuation of Vasopressin in Neurological Intensive Care Unit Patients: Case Series and Literature Review. ( 27742514 )
2017
3
Diabetes insipidus and the use of desmopressin in hospitalised children. ( 28073809 )
2017
4
Overlap of Post-obstructive Diuresis and Unmasked Diabetes Insipidus in a Case of IgG4-related Retroperitoneal Fibrosis and Tuberoinfundibular Hypophysitis: A Case Report and Review of the Literature. ( 28049999 )
2017
5
Adipsic diabetes insipidus in adult patients. ( 28074401 )
2017
6
Diabetes insipidus induced by suspected eosinophilic granulomatous with polyangiitis. ( 27807002 )
2016
7
Central diabetes insipidus as a very late relapse limited to the pituitary stalk in Langerhans cell histiocytosis. ( 27089406 )
2016
8
An unusual case of hereditary nephrogenic diabetes insipidus (HNDI) affecting mother and daughter. ( 26244674 )
2016
9
Poster 365 Traumatic Brain Injury Resulting from Pontine and Extrapontine Myelinolysis due to Acute Onset of Pregnancy Induced Diabetes Insipidus: A Case Report. ( 27673118 )
2016
10
4-PBA Improves Lithium-induced Nephrogenic Diabetes Insipidus by Attenuating ER Stress. ( 27385737 )
2016
11
Identification of five novel arginine vasopressin gene mutations in patients with familial neurohypophyseal diabetes insipidus. ( 27513365 )
2016
12
A novel AVPR2 gene mutation of X-linked congenital nephrogenic diabetes insipidus in an Asian pedigree. ( 27565746 )
2016
13
Diabetes insipidus uncovered during conservative management of complicated acute appendicitis. ( 27190614 )
2016
14
Physiological insights into novel therapies for nephrogenic diabetes insipidus. ( 27534996 )
2016
15
Diabetes insipidus: Differential diagnosis and management. ( 27156759 )
2016
16
Cholesteatoma in the Sellar Region Presenting as Hypopituitarism and Diabetes Insipidus. ( 26962793 )
2016
17
Diabetes insipidus and pregnancy. ( 27172867 )
2016
18
Bilateral Ossified Chronic Subdural Hematoma Presenting As Diabetes Insipidus- A Case Report and Literature Review. ( 27867130 )
2016
19
Animal models of Central Diabetes Insipidus: Human relevance of acquired beyond hereditary syndromes and the role of oxytocin. ( 27118135 )
2016
20
Diabetes Insipidus as an Initial Presentation of Myelodysplastic Syndrome: Diagnosis with Single-Nucleotide Polymorphism Array-Based Karyotyping. ( 27075406 )
2016
21
Buccally Administered Intranasal Desmopressin Acetate for the Treatment of Neurogenic Diabetes Insipidus in Infancy. ( 27011115 )
2016
22
Prevalence and risk factors for central diabetes insipidus in cardiac arrest survivor treated with targeted temperature management. ( 27133533 )
2016
23
Central diabetes insipidus. ( 28008190 )
2016
24
Central Diabetes Insipidus and Cisplatin-Induced Renal Salt Wasting Syndrome: A Challenging Combination. ( 26928867 )
2016
25
Acetazolamide in Lithium-Induced Nephrogenic Diabetes Insipidus. ( 27959610 )
2016
26
Spontaneous intermittent MRI changes of a pituitary stalk lesion causing diabetes insipidus and amenorrhea. ( 27655292 )
2016
27
Bendamustine-Induced Nephrogenic Diabetes Insipidus inA aA Patient With AL Amyloidosis. ( 27780577 )
2016
28
Pulmonary Langerhans Cell Histiocytosis and Diabetes Insipidus in a Young Smoker. ( 27445532 )
2016
29
A novel AVP gene mutation in a Turkish family with neurohypophyseal diabetes insipidus. ( 26208472 )
2016
30
[Analysis of AVPR2 gene mutation in a pedigree affected with congenital nephrogenic diabetes insipidus]. ( 27577218 )
2016
31
Two novel mutations in seven Czech and Slovak kindreds with familial neurohypophyseal diabetes insipidus-benefit of genetic testing. ( 27539621 )
2016
32
Pituitary Morphology and Function in 43 Children with Central Diabetes Insipidus. ( 27118970 )
2016
33
Signaling Modification by GPCR Heteromer and Its Implication on X-Linked Nephrogenic Diabetes Insipidus. ( 27649563 )
2016
34
Exacerbation of pre-existing diabetes insipidus during pregnancy, mechanisms and management. ( 27654225 )
2016
35
Novel AVPR2 mutation causing partial nephrogenic diabetes insipidus in a Japanese family. ( 26974133 )
2016
36
Diabetes insipidus in infants and children. ( 27156767 )
2016
37
Delayed recovery of adipsic diabetes insipidus (ADI) caused by elective clipping of anterior communicating artery and left middle cerebral artery aneurysms. ( 27977657 )
2016
38
Managing adipsic diabetes insipidus following anterior communicating artery aneurysm in a subtropical climate. ( 27386124 )
2016
39
INCIDENCE OF CENTRAL DIABETES INSIPIDUS IN CHILDREN PRESENTING WITH POLYDIPSIA AND POLYURIA. ( 27540876 )
2016
40
A novel mutation affecting the arginine-137 residue of AVPR2 in dizygous twins leads to nephrogenic diabetes insipidus and attenuated urine exosome aquaporin-2. ( 27117808 )
2016
41
Unusual Presentation of Central Diabetes Insipidus in a Patient With Neurosarcoidosis. ( 27652275 )
2016
42
Occult Langerhans Cell Histiocytosis Presenting with Papillary Thyroid Carcinoma, a Thickened Pituitary Stalk and Diabetes Insipidus. ( 27656301 )
2016
43
Diabetes insipidus during pregnancy. ( 27156766 )
2016
44
A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothers. ( 26795631 )
2016
45
Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus. ( 27478876 )
2016
46
Central diabetes insipidus: clinical profile that suggests organicity in Peruvian children: Lima - Peru 2001-2013. ( 27845884 )
2016
47
Cranial diabetes insipidus with pituitary stalk lesions. ( 27131387 )
2016
48
Prediction of postoperative diabetes insipidus using morphological hyperintensity patterns in the pituitary stalk on magnetic resonance imaging after transsphenoidal surgery for sellar tumors. ( 27586498 )
2016
49
Competing interests in a lung cancer with metastasis to the pituitary gland: syndrome of inappropriate ADH secretion versus diabetes insipidus. ( 27274855 )
2016
50
Dengue fever with diffuse cerebral hemorrhages, subdural hematoma and cranial diabetes insipidus. ( 27165581 )
2016

Variations for Diabetes Insipidus

Expression for Diabetes Insipidus

Search GEO for disease gene expression data for Diabetes Insipidus.

Pathways for Diabetes Insipidus

Pathways related to Diabetes Insipidus according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 AQP2 AQP3 AVP AVPR2 CLCNKA SLC12A1
2 12.13 AVP POMC SLC12A1 WFS1
3
Show member pathways
11.97 AQP2 AQP3 AVP AVPR2
4
Show member pathways
11.87 INS POMC REN
5 11.42 AVP AVPR2 CRH POMC
6 10.87 CLCNKA SLC12A1
7 10.57 AQP2 AQP3 AVP AVPR2
8 10 CRH POMC

GO Terms for Diabetes Insipidus

Cellular components related to Diabetes Insipidus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.96 INS PRL
2 secretory granule GO:0030141 8.8 AVP POMC PRL

Biological processes related to Diabetes Insipidus according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.73 AVP AVPR2 CRH INS
2 positive regulation of cell proliferation GO:0008284 9.65 AVP AVPR2 CRH INS PRL
3 response to ethanol GO:0045471 9.63 AVP CRH PRL
4 positive regulation of vasoconstriction GO:0045907 9.49 AVP AVPR2
5 response to immobilization stress GO:0035902 9.48 CRH REN
6 parturition GO:0007567 9.4 CRH PRL
7 positive regulation of systemic arterial blood pressure GO:0003084 9.37 AVP AVPR2
8 water transport GO:0006833 9.33 AQP2 AQP3 AVP
9 glycerol transport GO:0015793 9.32 AQP2 AQP3
10 excretion GO:0007588 9.26 AQP2 AQP3 AVPR2 CLCNKA
11 renal water homeostasis GO:0003091 9.02 AQP2 AQP3 AVP AVPR2 WFS1

Molecular functions related to Diabetes Insipidus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.56 AVP CRH POMC REN
2 neuropeptide hormone activity GO:0005184 9.32 AVP CRH
3 insulin-like growth factor receptor binding GO:0005159 9.16 INS REN
4 hormone activity GO:0005179 9.02 AVP CRH INS POMC PRL
5 water channel activity GO:0015250 8.96 AQP2 AQP3

Sources for Diabetes Insipidus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....